CardioQ-ODM Update

Deltex Medical Group PLC
08 May 2008


                            Deltex Medical Group plc

 Third major hospital in southern California implements use of CardioQ-ODM as
                           standard clinical practice

8 May 2008 - Deltex Medical Group plc ('Deltex Medical' or 'the Company'), the
UK's leading haemodynamic monitoring company, today announces that doctors at a
third major hospital in Southern California have embarked on the first phase of
a structured programme to implement routine use of the CardioQ-ODM in surgery
and intensive care.

The implementation is being led by anaesthetists from the third largest
independent anaesthetic services provider in the USA in conjunction with
surgeons, intensive care specialists and hospital managers.

Anaesthetists from the same group, working in the first hospital to implement
routine use of the CardioQ-ODM, have reported that private insurers, accounting
for approximately sixty-five percent of patients treated in their hospital, have
reimbursed all claims made by physicians for the use of the monitor. We also
understand that claims have been reimbursed at a level that is at the upper end
of user expectations.

Deltex Medical's Chief Executive, Andy Hill commented:

'While it was planned that anaesthetists at this third hospital would embark on
an implementation programme, I believe that the positive experience of their
colleagues and the level of reimbursement they have routinely received has
encouraged a much earlier start than originally envisaged.'

For further information, please contact:-

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman [e-mail]
Andy Hill, Chief Executive [e-mail]
Ewan Phillips, Finance Director [e-mail]

Gavin Anderson & Company 0207 554 1400

Deborah Walter  [e-mail]
Robert Speed    [e-mail]


Charles Stanley Securities 020 7149 6000 (Nominated Adviser)
Philip Davies   [e-mail]
Russell Cook    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the
amount of circulating blood significantly reduces post-operative complications
allowing patients to make a faster, more complete recovery and return home
earlier.


The CardioQ-ODM incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ-ODM provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals
worldwide and distribution arrangements are in place in over 30 countries. In
addition, there are currently more than 100 clinical publications on the use of
the CardioQ-ODM which have repeatedly:-


   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works


   •Proved that the CardioQ-ODM works in a wide range of surgical procedures


   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ-ODM in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange